Neuromuscular Blocking Agents

Pediatric Critical Care

Volumn , Issue , 2006, Pages 1729-1747

  Cook, D Ryan ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649906429     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-032301808-1.50118-8     Document Type: Chapter

References (149)

1. Elliot JM, Bion JF The use of neuromuscular blocking drugs in intensive care practice. Acta Anaesthesiol Scand 1995, 39:70.
2. Fiamengo SA, Savarese JJ Use of muscle relaxants in intensive care units. Crit Care Med 1991, 19:1457.
3. Fleming NW Neuromuscular blocking drugs in the intensive care unit: indications, protocols, and complications. Semin Anesth 1994, 13:255.
4. Kim C, Hirose M, Martyn JAJ d-Tubocurarine accentuates the burn-induced upregulation of nicotinic acetylcholine receptors at the muscle membrane. Anesthesiology 1995, 83:309-315.
5. Klessig HT, Geiger HJ, Murray MJ, et al. A national survey on the practice patterns of anesthesiologist intensivists in the use of muscle relaxants. Crit Care Med 1992, 20:1341.
6. Lee C Intensive care unit neuromuscular syndrome?. Anesthesiology 1995, 83:237.
7. Magorian T, Lynam DP Clinical use of muscle relaxants in patients with hepatic disease. Problems in anaesthesia: neuromuscular relaxants 1992, JB Lippincott, Philadelphia. S.M. Rupp (Ed.).
8. Martyn JAJ, White DA, Gronert GA, et al. Up-and-down regulation of skeletal muscle acetylcholine receptors. Anesthesiology 1992, 76:822-843.
9. Miller RD Use of neuromuscular blocking drugs in intensive care unit patients. Anesth Analg 1995, 81:1-2.
10. Rupp SM: Muscle relaxants and the patient with renal and/or hepatic failure. In Azar I, editor: Muscle relaxants. New York, 1993.
11. Viby-Mogensen J Monitoring neuromuscular function in the intensive care unit. Intensive Care Med 1993, 19(suppl):S74.
12. Watling SM, Dasta JF Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: a review of the literature. Crit Care Med 1994, 22:884.
13. Calakos N, Scheller RH Synaptic vesicle biogenesis, docking, and fusion: a molecular description. Physiol Rev 1996, 76:1-29.
14. Prince RJ, Since SM The ligand binding domains of the nicotinic acetylcholine receptor. The nicotinic acetylcholine receptor: current views and future trends 1998, Springer-Verlag, Berlin, New York. F.J. Barrantes (Ed.).
15. Sanes JR, Lichtman JW Development of vertebrate neuromuscular junction. Ann Rev Neurosci 1999, 22:389-442.
16. Blount P, Merlie JP Molecular basis of the two nonequivalent ligand binding sites of the muscle nicotinic acetylcholine receptor. Neuron 1989, 3:349.
17. Gu Y, Franco A, Gardner PD, et al. Properties of embryonic and adult muscle acetylcholine receptors transiently expressed in COS cells. Neuron 1990, 5:147.
18. Pedersen SE, Cohen JB d-Tubocurarine binding sites are located at a-g and a-d subunit interfaces of the nicotinic acetylcholine receptor. Proc Natl Acad Sci 1990, 87:2785.
19. Yost CS, Dodson BA Inhibition of the nicotinic acetylcholine receptor by barbiturates and by procaine: do they act at different sites?. Cell Mol Neurobiol 1993, 13:159.
20. Yost CS Fetal-type acetylcholine receptors are more sensitive than adult-type to pancuronium blockade at equipotent agonist concentration. Anesthesiology 1994, 81:3A.
21. Paul M, Kindler CH, Fokt RM, et al. The potency of new muscle relaxants on recombinant muscle-type acetylcholine receptors. Anesth Analg 2002, 94:597-603.
22. Paul M, Fokt RM, Kindler CH, et al. Characterization of the interactions between volatile anesthetics and neuromuscular blockers at the muscle nicotinic acetylcholine receptor. Anesth Analg 2002, 95:362-367.
23. Bowman WC Prejunctional and postjunctional cholinoreceptors at the neuromuscular junction. Anesth Analg 1980, 59:935.
24. Prielipp RC, Coursin DB, Scuderi PE, et al. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients. Crit Care Trauma 1995, 81:3.
25. Segredo V, Caldwell JE, Matthay MA, et al. Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 1992, 327:524.
26. Tobias JD, Lynch A, McDuffee A, et al. Pancuronium infusion for neuromuscular block in children in the pediatric intensive care unit. Anesth Analg 1995, 81:13.
27. Naguib M, Flood P, McArdle JJ, et al. Advances in neurobiology of the neuromuscular junction. Anesthesiology 2002, 96:202-231.
28. Lee C Structure, conformation, and action of neuromuscular blocking drugs. Br J Anaesth 1987, 5:755-769.
29. Wareham AC, Morton RH, Meakin GH Low quantal content of the endplate potential reduces safety factor for neuromuscular transmission in the diaphragm of the newborn rat. Br J Anaesth 1994, 72:205-209.
30. Meakin G, Morton RH, Wareham AC Age-dependent variation in response to tubocurarine in the isolated rat diaphragm. Br J Anaesth 1992, 68:161-163.
31. Goudsouzian NG Maturation of neuromuscular transmission in the infant. Br J Anaesth 1980, 52:205.
32. Crumrine RS, Yodlowski EH Assessment of neuromuscular function in infants. Anesthesiology 1981, 54:29.
33. Donati F, Bevan DR Long-term succinylcholine infusion during isoflurane. Anesthesiology 1983, 58:6.
34. Goudsouzian NG, Liu LMP The neuromuscular response of infants to a continuous infusion of succinylcholine. Anesthesiology 1984, 60:97.
35. Lee C Self antagonism: possible mechanism of tachyphylaxis in suxamethonium-induced neuromuscular block in man. Br J Anaesth 1986, 48:1097.
36. Sutherland GA, Bevan JC, Bevan DR Neuromuscular blockade in infants following intramuscular succinylcholine in two or five percent solution. Can J Anaesth 1980, 30:342.
37. Dahaba AA, von Klobucar F, Rehak PH, et al. The neuromuscular transmission module versus the relaxometer mechanomyogaph for neuromuscular block monitoring. Anesth Analg 2002, 94:591-596.
38. Kopman AF, Kumar S, Klewicka MM, et al. The staircase phenomenon: Implications for monitoring of neuromuscular transmission. Anesthesiology 2001, 95:403-407.
39. Kopman AF, Klewicka MM, Neuman GG Reexamined: The recommended endotracheal intubating dose for nondepolarizing neuromuscular blockers of rapid onset. Anesth Analg 2001, 93:954-959.
40. Kopman AF, Khan NA, Neuman GG Precurarization and priming: a theoretical analysis of safety and timing. Anesth Analg 2001, 93:1253-1256.
41. Tang TT, Oechler HW, Siker D, et al. Anesthesia-induced rhabdomyolysis in infants with unsuspected Duchenne dystrophy. Acta Paediatr 1992, 81:716-719.
42. Gronert GA Mortality greater with rhabdomyolysis than receptor upregulation. Anesthesiology 2001, 94:523-529.
43. Hopkins PM Use of suxamethonium in children. Br J Anaesth 1995, 75:675-677.
44. Cook DR, Fischer CG Neuromuscular blocking effects of succinylcholine in infants and children. Anesthesiology 1975, 42:662-665.
45. Meakin G, McKiernan EP, Morris P, et al. Dose-response curves for suxamethonium in neonates, infants and children. Br J Anaesth 1989, 62:655.
46. Heir T, Feiner JR, Lin J, et al. Hemoglobin desaturation after succinylcholine-induced apnea. Anesthesia 2001, 94:754-759.
47. Cook DR, Westman HR, Rosenfeld L, et al. Pulmonary edema in infants: possible association with intramuscular succinylcholine. Anesth Analg 1981, 60:220.
48. Minton MD, Grosslight K, Stirt JA, et al. Increases in intracranial pressure from succinylcholine: prevention by prior nondepolarizing blockade. Anesthesiology 1986, 65:165.
49. Delphin E, Jackson D, Rothstein P Use of succinylcholine during elective pediatric anesthesia should be reevaluated. Anesth Analg 1987, 66:1190.
50. Rosenberg H, Gronert GA Intractable cardiac arrest in children given succinylcholine. Anesthesiology 1992, 77:1054.
51. Schow AJ, Lubarsky DA, Olson RP, et al. Can succinylcholine be used safely in hyperkalemic patients?. Anesth Analg 2002, 95:119-122.
52. Dierdorf SF, McNiece WL, Wolfe TM, et al. Effect of thiopental and succinylcholine on serum potassium concentrations in children. Anesth Analg 1984, 63:1136.
53. Henning RD, Bush GH Plasma potassium after halothanesuxamethonium induction in children. Anaesthesia 1982, 37:802.
54. Harrington JF, Ford DJ, Striker TW Myoglobinemia and myoglobinuria after succinylcholine in children. Anesthesiology 1983, 59:A439.
55. Flewellen EH, Nelson TE Halothane-succinylcholine induced masseter spasm: indicative of malignant hyperthermia susceptibility. Anesth Analg 1984, 63:693.
56. Schwartz L, Rockoff MA, Koka BV Masseter spasm with anesthesia: incidence and implications. Anesthesiology 1984, 61:772.
57. DeCook TH, Goudsouzian NG Tachyphylaxis and phase II block development during infusion of succinylcholine in children. Anesth Analg 1980, 59:639.
58. Plumley MH, Bevan JC, Saddler JM, et al. Dose-related effects of succinylcholine on the adductor pollicis and masseter muscles in children. Can J Anaesth 1989, 37:15.
59. Saddler JM, Bevan JC, Plumley MH, et al. Jaw tension after succinylcholine in children undergoing strabismus surgery. Can J Anaesth 1989, 37:21.
60. Van der Spek AF, Reynolds PI, Ashton-Miller JA, et al. Differing effect of agonist and antagonist muscle relaxants on cat jaw muscles. Anesth Analg 1989, 69:76.
61. Van der Spek AF, Fang WB, Ashton-Miller JA, et al. Increased masticatory muscle stiffness during limb muscle flaccidity associated with succinylcholine administration. Anesthesiology 1988, 69:11.
62. Cook DR Can succinylcholine be abandoned?. Anesth Analg 2000, 90:S24-S28.
63. Bencini A, et al. Clinical pharmacokinetics of vecuronium. Clinical experiences with Norcuron (Org NC 45 vecuronium bromide) 1983, Excerpta Medica, Amsterdam. S. Agoston (Ed.).
64. Savage DS, Sleigh T, Carlyle I The emergence of ORG NC 45 from the pancuronium series. Br J Anaesth 1980, 52:3S.
65. Marshall IG, Gibb AJ, Durant NN Neuromuscular and vagal blocking actions of pancuronium bromide, its metabolites, and vecuronium bromide (ORG NC 45) and its potential metabolites in the anesthetized cat. Br J Anaesth 1983, 55:703.
66. Goudsouzian NG, Liu LMP, Cote CJ Comparison of equipotent doses of non-depolarizing muscle relaxants in children. Anesth Analg 1981, 60:862.
67. Goudsouzian NG, Martyn JJA, Liu LMP The dose response effect of long-acting non-depolarizing neuromuscular blocking agents in children. Can J Anaesth 1984, 3:246.
68. Cook DR Sensitivity of the newborn to tubocurarine. Br J Anaesth 1981, 53:320.
69. Fisher DM, O'Keeffe C, Stanski DR, et al. Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults. Anesthesiology 1982, 57:203.
70. Blinn A, Woelfel SK, Cook DR, et al. Pancuronium dose-response revisited. Paediatr Anesthe 1992, 2:153.
71. Duvaldestin P, Saada J, Berger JL, et al. Pharmacokinetics, pharmacodynamics, and dose-response relationships of pancuronium in control and elderly subjects. Anesthesiology 1982, 56:36.
72. Lavine LM, Hindein BI Hemodialysis as treatment for prolonged neuromuscular blockade in anephric patients. Anesthesiology 1983, 59:264.
73. Pittet JF, Tassonyi E, Morel DR, et al. Pipecuronium-induced neuromuscular blockade during nitrous oxide-fentanyl, isoflurane, and halothane anesthesia in adults and children. Anesthesiology 1989, 71:210.
74. Sarner JB, Brandom BW, Dong ML, et al. Clinical pharmacology of pipecuronium in infants and children during halothane anesthesia. Anesth Analg 1990, 71:362.
75. Caldwell JE, Canfell PC, Castagnoli KP, et al. The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide. Anesthesiology 1989, 70:7.
76. Caballero PA, Johnson RE Long-lasting neuromuscular blockade from pipecuronium. Anesthesiology 1992, 76:154.
77. Sarner JB, Brandom BW, Cook DR, et al. Clinical pharmacology of doxacurium chloride (BW A938U) in children. Anesth Analg 1988, 67:303-306.
78. Dresner DL, Basta SJ, Ali HA, et al. Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia. Anesth Analg 1990, 71:498.
79. Cook DR, Freeman JA, Lai AA, et al. Pharmacokinetics and pharmacodynamics of doxacurium in normal patients and in those with hepatic or renal failure. Anesth Analg 1991, 72:145.
80. Brandom BW, Cook DR, Woelfel SK, et al. Atracurium infusion in children during fentanyl, halothane, and isoflurane anesthesia. Anesth Analg 1985, 64:471.
81. Goudsouzian NG, et al. Neuromuscular effect of atracurium in infants and children. Anesthesiology 1985, 62:75.
82. Goudsouzian NG, Liu LM, Cote CJ, et al. Safety and efficacy of atracurium in adolescents and children anesthetized with halothane. Anesthesiology 1983, 59:459.
83. Stiller RL, Brandom BW, Cook DR Determination of atracurium by high-performance liquid chromatography. Anesth Analg 1985, 64:58.
84. Stiller RL, Cook DR, Chakravorti S In vitro degradation of atracurium in human plasma. Br J Anaesth 1985, 57:1085.
85. d'Hollander AA, Luyckx C, Barvais L, et al. Clinical evaluation of atracurium besylate requirement for a stable muscle relaxation during surgery: lack of age-related effects. Anesthesiology 1983, 59:237.
86. Neill EAM, Chapple DJ Metabolic studies in the cat with atracurium: neuromuscular blocking agent designed for non-enzymatic inactivation at physiological pH. Xenobiotica 1983, 12:203.
87. Fahey MR, Rupp SM, Fisher DM, et al. The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. Anesthesiology 1984, 61:699.
88. Hunter JM, Jones RS, Utting JE Use of atracurium in patients with no renal function. Br J Anaesth 1982, 54:1251.
89. Ward S, Neil EAM Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure). Br J Anaesth 1983, 55:1169.
90. Welch RM, Brown A, Ravitch J, et al. The in vitro degradation of cisatracurium, the R, cis-R'-isomer of atracurium, in human and rat plasma. Clin Pharmacol Ther 1995, 58:132.
91. Babel A Etude comparative de la laudanosine et de la papaverine au point de vue pharmacodynamique. Rev Med Suisse Romande 1989, 19:657.
92. Tobias JD, Johnson JO, Sprague K, et al. Effects of rapacuronium on respiratory function during general anesthesia. Anesthesiology 2001, 95:908-912.
93. DeWolf AM, Freeman JA, Scott VL, et al. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. Br J Anesth 1996, 76:624.
94. Dhonneur G, Cerf C, Lagneau F, et al. The pharmacokinetics of cisatracurium in patients with acute respiratory distress syndrome. Anesth Analg 2001, 93:400-404.
95. Reich DL, Hollinger I, Harrington DJ et al: Pharmacokinetic comparison of cisatracurium and vecuronium infusions in neonates and infants following congenital heart surgery. Anesthesiology, October 2002.
96. Eddleston JM, Harper NJ, Pollard BJ, et al. Concentrations of atracurium and laudanosine in cerebrospinal fluid during intracranial surgery. Br J Anaesth 1989, 63:525.
97. Parker CJR, Jones JE, Hunter JM Disposition of atracurium and its metabolite, laudanosine, in patients in renal and respiratory failure in an ITU. Br J Anaesth 1988, 61:531.
98. Fahey MR, Rupp SM, Canfell C, et al. The effect of renal failure on laudanosine excretion in man. Br J Anaesth 1985, 57:1049.
99. Ingram MD, Sclabassi RJ, Cook DR, et al. Cardiovascular and electroencephalographic effects of laudanosine in 'nephrectomized' cats. Br J Anaesth 1986, 58:14S.
100. Shi WZ, Fahey MR, Fisher DM, et al. Laudanosine (a metabolite of atracurium) increases the minimum alveolar concentration of halothane in rabbits. Anesthesiology 1985, 63:584.
101. Lanier WL, Milde JH, Michenfelder JD The cerebral effects of pancuronium and atracurium in halothane-anesthetized dogs. Anesthesiology 1985, 63:589.
102. Chiodini F, Charpantier E, Muller D, et al. Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine. Anesthesiology 2001, 94:643-651.
103. d'Hollander A, Massaux F, Nevelsteen M, et al. Age-dependent dose-response relationship of ORG NC45 in anesthetized patients. Br J Anaesth 1982, 54:653.
104. Fisher DM, Cronnelly R, Miller RD, et al. The neuromuscular pharmacology of neostigmine in infants and children. Anesthesiology 1983, 59:220.
105. Woelfel SK, Brandom BW, Cook DR, et al. Effects of bolus administration of ORG-9426 in children during nitrous oxide-halothane anesthesia. Anesthesiology 1992, 76:939.
106. Gatke MR, Ostergaard D, Bundgaard JR, et al. Response to mivacurium in a patient compound heterozygous for a novel and a known silent mutation in the butyrylcholinesterase gene: genotyping by sequencing. Anesthesiology 2001, 95:600-606.
107. 2O-halothane anesthesia. Anesthesiology 1983, 58:519.
108. Duvaldestin P, et al. Pharmacokinetics and pharmacodynamics of ORG NC 45 in patients with cirrhosis. Anesthesiology 1982, 57:A238.
109. Lynam DP, Cronnelly R, Castagnoli KP, et al. The pharmacodynamics and pharmacokinetics of vecuronium in patients anesthetized with isoflurane with normal renal function or with renal failure. Anesthesiology 1988, 69:227.
110. Kopman A Pancuronium, gallamine, and d-tubocurarine compared: Is speed of onset inversely related to drug potency?. Anesthesiology 1989, 70:915.
111. 2O-halothane anesthesia. Anesthesiology 1991, 76:A787.
112. Meretoja OA Is vecuronium a long-acting neuromuscular blocking agent in neonates and infants?. Br J Anaesth 1989, 62:184.
113. Khuenl-Brady K, Castagnoli KP, Canfell C, et al. The neuromuscular blocking effects and pharmacokinetics of ORG 9426 and ORG 9616 in the cat. Anesthesiology 1990, 72:669-674.
114. Cooper RA, Maddineni VR, Mirakhur RK, et al. Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (ORG 9426) during isoflurane anesthesia in patients with and without renal failure. Br J Anaesth 1993, 71:222.
115. Cook DR, Chakravorti S, Brandom BW, et al. Effects of neostigmine, edrophonium and succinylcholine on the in vitro metabolism of mivacurium: clinical correlates. Anesthesiology 1992, 77:A948.
116. Ostergaard D, Rasmussen SN, Vib-Mogensen J, et al. The influence of drug-induced low plasma cholinesterase activity on the pharmacokinetics and pharmacodynamics of mivacurium. Anesthesiology 2000, 92:1581-1587.
117. Beaufort TM, Nigrovic V, Proost JH, et al. Inhibition of the enzymic degradation of suxamethonium and mivacurium increases the onset time of submaximal neuromuscular block. Anesthesiology 1998, 89:707-714.
118. Cook DR, Freeman JA, Lai AA, et al. Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure. Br J Anaesth 1992, 69:580.
119. Head-Rapson AG, Devlin JC, Parker CJR, et al. Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. Br J Anaesth 1994, 73:613.
120. Lien CA, Schmith VD, Embree PB, et al. The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1994, 80:1296.
121. Meretoja OA, Taivainen T, Wirtavuori K Pharmacodynamics of mivacurium in infants. Br J Anaesth 1994, 73:490.
122. Woelfel SK, Brandom BW, McGowan FX, et al. Clinical pharmacology of mivacurium in pediatric patients less than two years old during nitrous oxide-halothane anesthesia. Anesth Analg 1993, 77:713.
123. Gronert BJ, Woelfel SK, Cook DR Comparison of the neuromuscular effects of mivacurium and succinylcholine in infants and children. Acta Anaesthesiol Scand 1995, 39:35.
124. Gronert B, Woelfel S, Cook DR Comparison of equipotent intubating doses of mivacurium and succinylcholine in infants 2-12 months old. Anesthesiology 1993, 79:A932.
125. Gronert BJ, Brandom Neuromuscular blocking drugs in infants and children. Pediatr Clin North Am 1994, 41:73.
126. Gronert B, Woelfel S, Cook DR Comparison of equipotent doses of mivacurium and succinylcholine in children 2-12 years old. Anesthesiology 1993, 79:A966.
127. Fine GF, Motoyama EK, Brandom BW, et al. The effect on lung mechanics in anesthetized children with rapacuronium: A comparative study with mivacurium. Anesth Analg 2002, 95:56-61.
128. Ostergaard D, Gatke MR, Rasmussen BH, et al. The pharmacodynamics and pharmacokinetics of mivacurium in children. Acta Anaesthesiol Scand 2002, 46:512-518.
129. Markakis DA, Lau M, Brown R, et al. The pharmacokinetics and steady state pharmacodynamics of mivacurium in children. Anesthesiology 1998, 88:978-983.
130. Brandom BW, Sarner JB, Woelfel SK, et al. Mivacurium infusion requirements in pediatric surgical patients during nitrous oxide-halothane and during nitrous oxide-narcotic anesthesia. Anesth Analg 1990, 71:16.
131. Goudsouzian N, Chakravorti S, Denman W, et al. Lack of accumulation of the cis-cis isomer of mivacurium in patients with low plasma cholinesterase activity. Anesthesiology 1994, 81:1060.
132. Head-Rapson AG, Devlin JC, Parker CJ, et al. Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. Br J Anaesth 1995, 75:31-36.
133. Head-Rapson AG, Devlin JC, Parker CJ, et al. Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. Br J Anaesth 1994, 73:613-618.
134. Levy G Effect of hepatic cirrhosis on the pharmacodynamics and pharmacokinetics of mivacurium in humans. Pharm Res 1994, 11:772-773.
135. Brandom BW, Woelfel SK, Cook DR, et al. Clinical pharmacology of atracurium in infants. Anesth Analg 1984, 63:309.
136. Brandom BW, Rudd GD, Cook DR Clinical pharmacology of atracurium in pediatric patients. Br J Anaesth 1983, 55:117S.
137. Basta SJ, Savarese JJ, Ali HH, et al. Histamine-releasing potencies of atracurium dimethyltubocurarine and tubocurarine. Br J Anaesth 1983, 55:105.
138. Basta SJ, Savareses JJ, Ali HH, et al. Vecuronium does not alter serum histamine within the clinical dose range. Anesthesiology 1983, 59:A273.
139. Nightingale DA, Bush GH Atracurium in paediatric anesthesia. Br J Anaesth 1983, 55:115S.
140. Koppert W, Blunk JA, Petersen LJ Different patterns of mast cel activation by muscle relaxants in human skin. Anesthesiology 2001, 95:659-667.
141. Harper NJ, Greer R, Conway D Neuromuscular monitoring in intensive care patients: milliamperage requirements for supramaximal stimulation. Br J Anaesth 2001, 87:625-627.
142. Pavlin EG, Halle RH, Schaene R Recovery of airway protection compared with ventilation in humans after paralysis with curare. Anesthesiology 1989, 70:381.
143. Viby-Mogensen J, Jensen NH, Engbaek J, et al. Tactile and visual evaluation of the response to train-of-four stimulation. Anesthesiology 1985, 63:440.
144. Drenck NE, Ueda N, Olsen NV, et al. Manual evaluation of residual curarization using double burst stimulation: a comparison with train-of-four. Anesthesiology 1989, 70:578.
145. De Jonghe B, Sharshar T, Lefaucheur JP, et al. Paresis acquired in the intensive care unit. JAMA 2002, 288:2859-2867.
146. Fine GF, Brandom BW, Yellon RF Unmasked residual neuromuscular block after administration of vecuronium for days. Anesth Analg 2001, 93:345-347.
147. Shear CR Effects of disuse on growing and adult chick skeletal muscle. J Cell Sci 1981, 48:35.
148. Fisher DM, Cronnelly R, Sharma M, et al. Clinical pharmacology of edrophonium in infants. Anesthesiology 1984, 61:428.
149. Meakin G, Sweet PT, Bevan JC, et al. Neostigmine and edrophonium as antagonists of pancuronium in infants and children. Anesthesiology 1983, 59:316.